Company / Financials
Protagenic Therapeutics, Inc.new Financials
FY2014-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$0
FY2024
Net Income
-$5.5M
FY2024 · -10.5% YoY
Profit Margin
-
FY2024 · net income / revenue
ROE
-545.4%
FY2024 · return on equity
Total Assets
$2.0M
FY2024
Total Debt
-
FY2024
Equity
$1.0M
FY2024
ROA
-282.5%
FY2024 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -23.98 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 1/9 criteria passed
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$0Net Income HistoryProfit after all expenses and taxes-$5.5M-10.5% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$5.7M-25.9% YoYSG&A Expense HistorySelling, general, and administrative expenses$1.8M+45.7% YoYR&D Expense HistoryResearch and development spending$3.8M+25.5% YoYInterest Expense HistoryCost of borrowing and debt obligations-Income Tax HistoryTotal income tax expense-EPS (Basic) HistoryBasic earnings per share-$1.15-40.2% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$1.15-40.2% YoYShares Outstanding HistoryWeighted average diluted shares outstanding4.4M+2.6% YoY